Abishai Financial Asia Covers AZ Elecoglipron Phase 3
Phase 2 obesity and diabetes data for the oral GLP-1 receptor agonist meets co-primary endpoints, sharpening competition with Novo Nordisk and Eli Lilly as healthcare allocators weigh cardiometabolic exposure and Phase 3 risk. AstraZeneca’s oral GLP-1 receptor agonist elecoglipron is advancing towards Phase 3 development, with Phase 2 trials meeting their co-primary endpoints, a milestone…